Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lorcaserin

- PMLiVE

US says medicine ads should include list prices

Hopes the proposal will encourage lower prescription drug prices

- PMLiVE

AcelRX’s potent opioid tablets set to win FDA backing for pain relief

Panel voted 10 to 3 in favour of the treatment

- PMLiVE

Novartis files for approval of MS drug in EU, US

Siponimod could achieve blockbuster status if approved, says analysts

- PMLiVE

Insmed claims first FDA okay for limited population antibiotic

Arikayce is cleared to treat lung disease caused by MAC

- PMLiVE

Biotech leaders jump into US free speech debate

Senior biotech execs sign a letter in defence of free speech

- PMLiVE

FDA gives Loxo breakthrough tag for second cancer drug

US regulatory body to expect a NDA for LOXO-292 in late 2019

- PMLiVE

Novartis sells off part of Sandoz portfolio

Swiss pharma giant will retain biosimilars

- PMLiVE

Shire claims US okay for HAE blockbuster-in-waiting

FDA approves Takhzyro as a preventative measure for HAE attacks

EISAI

Eisai’s Lenvima wins European liver cancer indication

EC green-lights the RTK inhibitor as a first-line treatment

- PMLiVE

Novo Nordisk and Evotec inks drug development deal

Will develop drugs for obesity and diabetes

- PMLiVE

FDA clears Kyowa Kirin’s skin lymphoma therapy Poteligeo

Becomes the first drug approved to treat Sézary syndrome

- PMLiVE

Pfizer CEO reckons rebates will disappear, and that’s a positive

The move also has the support of FDA Commissioner Scott Gottlieb

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links